A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. An experimental vaccine ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and year ended December 31, 2025.

Dear Dr. Roach: About one year ago, I had Clostridioides difficile (C. diff) that was treated with 125 mg of vancomycin for about four weeks. I had none of the usual risk factors, and the cause was ...

Nashville, Tenn.-based Vanderbilt Health researchers have developed a promising novel vaccine to treat Clostridioides difficile infections. Previous vaccine strategies targeted the bacterium’s primary ...

The U.S. Centers for Disease Control and Prevention (CDC) has issued a travel warning for Americans headed to the Seychelles over an outbreak of chikungunya diseasre virus. The CDC’s Level 2 travel ...

Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas Multiple Material Transfer Agreements signed ...

Norovirus, which is most often spread through contaminated food or water, has been making its rounds again during the winter season. While the symptoms can hit hard and fast, the small silver lining ...

PARIS: Named for the Malaysian village where it was first identified, the Nipah virus is an infectious disease transmitted primarily by bats. Often fatal, its potential to spread has so far been ...

Dr. Roach: About one year ago, I had Clostridioides difficile (C. diff) that was treated with 125 mg of vancomycin for about four weeks. I had none of the usual risk factors, and the cause was never ...

Seal Shield LLC, a global leader in hygienic medical-grade devices, today announced the strategic acquisition of Vioguard, a Washington State-based company known for its innovative UV-C keyboard ...